TITAN: Inference of copy number architectures in clonal cell populations from tumor whole-genome sequence data

Genome Research

Volumn 24, Issue 11, 2014, Pages 1881-1893

  Ha, Gavin ^a,b   Roth, Andrew ^a,b   Khattra, Jaswinder ^a   Ho, Julie ^c   Yap, Damian ^a   Prentice, Leah M ^c   Melnyk, Nataliya ^c   McPherson, Andrew ^a,b   Bashashati, Ali ^a   Laks, Emma ^a   Biele, Justina ^a   Ding, Jiarui ^a,b   Le, Alan ^a   Rosner, Jamie ^a   Shumansky, Karey ^a   Marra, Marco A ^a   Gilks, C Blake ^d   Huntsman, David G ^c,e   McAlpine, Jessica N ^b   Aparicio, Samuel ^a,e   Shah, Sohrab P ^a,b,e   more..

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c Centre for Translational and Applied Genomics   (Canada)

^d VANCOUVER GENERAL HOSPITAL   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ALLELIC IMBALANCE; ARTICLE; CANCER GENETICS; CELL POPULATION; CLONAL EVOLUTION; COPY NUMBER VARIATION; DNA SEQUENCE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DOSAGE; GENE SEQUENCE; HETEROZYGOSITY LOSS; HUMAN; MULTIPLE CANCER; OVARY CANCER; POINT MUTATION; POPULATION STRUCTURE; PRIORITY JOURNAL; SINGLE CELL ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL CONCEPTS; TITAN; TRIPLE NEGATIVE BREAST CANCER; ALGORITHM; BIOLOGICAL MODEL; BIOLOGY; CELL CLONE; FEMALE; GENETICS; GENOMICS; GENOTYPE; METABOLISM; NEOPLASM; OVARY TUMOR; PATHOLOGY; PROCEDURES; REPRODUCIBILITY;

ALGORITHMS; CLONE CELLS; COMPUTATIONAL BIOLOGY; DNA COPY NUMBER VARIATIONS; FEMALE; GENOMICS; GENOTYPE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LOSS OF HETEROZYGOSITY; MODELS, GENETIC; NEOPLASMS; OVARIAN NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; REPRODUCIBILITY OF RESULTS; SEQUENCE ANALYSIS, DNA; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84924336542     PISSN: 10889051     EISSN: 15495469     Source Type: Journal    
DOI: 10.1101/gr.180281.114     Document Type: Article

References (37)

1. Ahmed AA, Etemadmoghadam D, Temple J, Lynch AG, Riad M, Sharma R, Stewart C, Fereday S, Caldas C, Defazio A, et al. 2010. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol 221: 49-56.
2. Aparicio S, Caldas C. 2013. The implications of clonal genome evolution for cancer medicine. N Engl J Med 368: 842-851.
3. Bashashati A, Ha G, Tone A, Ding J, Prentice LM, Roth A, Rosner J, Shumansky K, Kalloger S, Senz J, et al. 2013. Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling. J Pathol 231: 21-34.
4. Benjamini Y, Hochberg Y. 1995. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc B Met 57: 289-300.
5. Boeva V, Popova T, Bleakley K, Chiche P, Cappo J, Schleiermacher G, Janoueix-Lerosey I, Delattre O, Barillot E. 2012. Control-FREEC: a tool for assessing copy number and allelic content using next-generation sequencing data. Bioinformatics 28: 423-425.
6. The Cancer Genome Atlas Research Network. 2011. Integrated genomic analyses of ovarian carcinoma. Nature 474: 609-615.
7. Carter SL, Cibulskis K, Helman E, McKenna A, Shen H, Zack T, Laird PW, Onofrio RC, Winckler W, Weir BA, et al. 2012. Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol 30: 413-421.
8. Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, Gabriel S, Meyerson M, Lander ES, Getz G, et al. 2013. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol 31: 213-219.
9. Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS, Ritchey JK, Young MA, Lamprecht T, McLellan MD, et al. 2012. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 481: 506-510.
10. Fischer A, Vazquez-Garcia I, Illingworth CJR, Mustonen V. 2014. High-definition reconstruction of clonal composition in cancer. Cell Rep 7: 1740-1752.
11. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, et al. 2012. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366: 883-892.
12. Gerlinger M, Horswell S, Larkin J, Rowan AJ, Salm MP, Varela I, Fisher R, McGranahan N, Matthews N, Santos CR, et al. 2014. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genet 46: 225-233.
13. Gerstung M, Beisel C, Rechsteiner M, Wild P, Schraml P, Moch H, Beerenwinkel N. 2012. Reliable detection of subclonal single-nucleotide variants in tumour cell populations. Nat Commun 3: 811.
14. Greaves M, Maley CC 2012. Clonal evolution in cancer. Nature 481:306-313.
15. Ha G, Roth A, Lai D, Bashashati A, Ding J, Goya R, Giuliany R, Rosner J, Oloumi A, Shumansky K, et al. 2012. Integrative analysis of genome-wide loss of heterozygosity and monoallelic expression at nucleotide resolution reveals disrupted pathways in triple-negative breast cancer. Genome Res 22: 1995-2007.
16. Halkidi M, Batistakis Y, Vazirgiannis M. 2002. Clustering validity checking methods: part ii. SIGMOD Rec 31: 19-27.
17. The International Cancer Genome Consortium. 2010. International network of cancer genome projects. Nature 464: 993-998.
18. Landau DA, Carter SL, Stojanov P, McKenna A, Stevenson K, Lawrence MS, Sougnez C, Stewart C, Sivachenko A, Wang L, et al. 2013. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 152: 714-726.
19. Larson NB, Fridley BL. 2013. PurBayes: estimating tumor cellularity and subclonality in next-generation sequencing data. Bioinformatics 29: 1888-1889.
20. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R, Subgroup GPDP, et al. 2009. The sequence alignment/map format and SAMtools. Bioinformatics 25: 2078-2079.
21. Lord CJ, Ashworth A. 2012. The DNA damage response and cancer therapy. Nature 481: 287-294.
22. Mukhopadhyay A, Plummer ER, Elattar A, Soohoo S, Uzir B, Quinn JE, McCluggage WG, Maxwell P, Aneke H, Curtin NJ, et al. 2012. Clinicopathological features of homologous recombination-deficient epithelial ovarian cancers: sensitivity to PARP inhibitors, platinum, and survival. Cancer Res 72: 5675-5682.
23. Navin N, Kendall J, Troge J, Andrews P, Rodgers L, McIndoo J, Cook K, Stepansky A, Levy D, Esposito D, et al. 2011. Tumour evolution inferred by single-cell sequencing. Nature 472: 90-94.
24. Nik-Zainal S, Van Loo P, Wedge DC, Alexandrov LB, Greenman CD, Lau KW, Raine K, Jones D, Marshall J, Ramakrishna M, et al. 2012. The life history of 21 breast cancers. Cell 149: 994-1007.
25. Nowell PC. 1976. The clonal evolution of tumor cell populations. Science 194: 23-28.
26. Oesper L, Mahmoody A, Raphael BJ. 2013. THetA: inferring intra-tumor heterogeneity from high-throughput DNA sequencing data. Genome Biol 14: R80.
27. Potter NE, Ermini L, Papaemmanuil E, Cazzaniga G, Vijayaraghavan G, Titley I, Ford A, Campbell P, Kearney L, Greaves M, et al. 2013. Single-cell mutational profiling and clonal phylogeny in cancer. Genome Res 23: 2115-2125.
28. Roth A, Khattra J, Yap D, Wan A, Laks E, Biele J, Ha G, Aparicio S, Bouchard-Cote A, Shah SP, et al. 2014. PyClone: statistical inference of clonal population structure in cancer. Nat Methods 11: 396-398.
29. Shah SP, Morin RD, Khattra J, Prentice L, Pugh T, Burleigh A, Delaney A, Gelmon K, Guliany R, Senz J, et al. 2009. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 461: 809-813.
30. Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, Turashvili G, Ding J, Tse K, Haffari G, et al. 2012. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486: 395-399.
31. Sottoriva A, Spiteri I, Piccirillo SGM, Touloumis A, Collins VP, Marioni JC, Curtis C, Watts C, Tavare S. 2013. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci 110: 4009-4014.
32. Van Loo P, Nordgard SH, Lingjærde OC, Russnes HG, Rye IH, Sun W, Weigman VJ, Marynen P, Zetterberg A, Naume B, et al. 2010. Allele-specific copy number analysis of tumors. Proc Natl Acad Sci 107: 16910-16915.
33. Wang ZC, Birkbak NJ, Culhane AC, Drapkin R, Fatima A, Tian R, Schwede M, Alsop K, Daniels KE, Piao H, et al. 2012. Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome. Clin Cancer Res 18: 5806-5815.
34. Xi R, Hadjipanayis AG, Luquette LJ, Kim TM, Lee E, Zhang J, Johnson MD, Muzny DM, Wheeler DA, Gibbs RA, et al. 2011. Copy number variation detection in whole-genome sequencing data using the Bayesian information criterion. Proc Natl Acad Sci 108: E1128-E1136.
35. Yang L, Luquette LJ, Gehlenborg N, Xi R, Haseley PS, Hsieh CH, Zhang C, Ren X, Protopopov A, Chin L, et al. 2013. Diverse mechanisms of somatic structural variations in human cancer genomes. Cell 153: 919-929.
36. Yau C. 2013. OncoSNP-SEQ: a statistical approach for the identification of somatic copy number alterations from next-generation sequencing of cancer genomes. Bioinformatics 29: 2482-2484.
37. Yau C, Mouradov D, Jorissen RN, Colella S, Mirza G, Steers G, Harris A, Ragoussis J, Sieber O, Holmes CC, et al. 2010. A statistical approach for detecting genomic aberrations in heterogeneous tumor samples from single nucleotide polymorphism genotyping data. Genome Biol 11: R92.